Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

BACKGROUND AND OBJECTIVE: Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated with chronic kidney disease. This study evaluated the effects of moderate hepatic impairment on roxadustat pharmacokinetics, pharmacodynami...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Drug Investig
Главные авторы: Groenendaal-van de Meent, Dorien, Adel, Martin den, Noukens, Jan, Rijnders, Sanne, Krebs-Brown, Axel, Mateva, Lyudmila, Alexiev, Assen, Schaddelee, Marloes
Формат: Artigo
Язык:Inglês
Опубликовано: Springer International Publishing 2016
Предметы:
Original Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4987405/
https://ncbi.nlm.nih.gov/pubmed/27352308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-016-0422-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы